Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Key market highlights PART 05: An overview of iron deficiency PART 06: Pipeline landscape PART 07: Market landscape • Market overview • Five forces analysis PART 08: Market segmentation by product type • Ferric carboxymaltose • Sucrose • Dextran • Others PART 09: Geographical segmentation • Intravenous iron drugs market in Americas • Intravenous iron drugs market in EMEA • Intravenous iron drugs market in APAC PART 10: Decision framework PART 11: Drivers and challenges • Market drivers • Impact of drivers on key customer segments • Market challenges • Impact of challenges on key customer segments PART 12: Market trends • Increase in favorable guidelines from healthcare organizations • Increasing strategies of vendors to expand reach of intravenous iron drugs • Growing focus on emerging economies PART 13: Vendor landscape • Competitive scenario PART 14: Key vendor analysis • Allergan • AMAG Pharmaceuticals • Daiichi Sankyo • Galenica • Pharmacosmos • Other prominent vendors PART 15: Appendix • List of abbreviation List of Exhibits Exhibit 01: Pipeline landscape Exhibit 02: Global intravenous iron drugs market Exhibit 03: Annual shipment sales growth of Ferinject/Injectafer in key countries in 2015 Exhibit 04: Global intravenous iron drugs market 2016-2021 ($ millions) Exhibit 05: Global intravenous iron drugs market: Opportunity analysis Exhibit 06: Five forces analysis Exhibit 07: Market segmentation by product type 2016 Exhibit 08: Ferric carboxymaltose-based intravenous iron drugs market 2016-2021 ($ millions) Exhibit 09: Global sucrose-based intravenous iron drugs market 2016-2021 ($ millions) Exhibit 10: Global dextran-based intravenous iron drugs market 2016-2021 ($ millions) Exhibit 11: Global other intravenous iron drugs market 2016-2021 ($ millions) Exhibit 12: Global intravenous iron drugs market by geography 2016 and 2021 Exhibit 13: Global intravenous iron drugs market by geography: Revenue 2016-2021 ($ millions) Exhibit 14: Market scenario in Americas Exhibit 15: Intravenous iron drugs market in the Americas 2016-2021 ($ millions) Exhibit 16: Market scenario in EMEA Exhibit 17: Intravenous iron drugs market in EMEA 2016-2021 ($ millions) Exhibit 18: Market scenario in APAC Exhibit 19: Intravenous iron drugs market in APAC 2016-2021 ($ millions) Exhibit 20: Impact of drivers Exhibit 21: Cost comparison of key drugs per week 2015 ($) Exhibit 22: Cost comparison of key drugs per treatment 2015 ($) Exhibit 23: Impact of challenges Exhibit 24: Competitive structure analysis of global intravenous iron drugs market 2016 Exhibit 25: Market share analysis 2016 Exhibit 26: Competitive analysis of global intravenous iron drugs market Exhibit 27: Strategic success factors of companies in global intravenous iron drugs market Exhibit 28: Allergan: Strength assessment Exhibit 29: Allergan: Strategy assessment Exhibit 30: Allergan: Opportunity assessment Exhibit 31: AMAG Pharmaceuticals: Key highlights Exhibit 32: AMAG Pharmaceuticals: Strength assessment Exhibit 33: AMAG Pharmaceuticals: Strategy assessment Exhibit 34: AMAG Pharmaceuticals: Opportunity assessment Exhibit 35: AMAG Pharmaceuticals: YoY revenue and growth rate of Feraheme ($ millions) Exhibit 36: Daiichi Sankyo: Key highlights Exhibit 37: Daiichi Sankyo: Strength assessment Exhibit 38: Daiichi Sankyo: Strategy assessment Exhibit 39: Daiichi Sankyo: Opportunity assessment Exhibit 40: Daiichi Sankyo: YoY revenue and growth rate of Injectafer 2013-2015 ($ millions) Exhibit 41: Daiichi Sankyo: YoY revenue and growth rate of Venofer 2013-2015 ($ millions) Exhibit 42: Galenica: Key highlights Exhibit 43: Galenica: Strength assessment Exhibit 44: Galenica: Strategy assessment Exhibit 45: Galenica: Opportunity assessment Exhibit 46: Galenica: YoY revenue and growth rate of Ferinject 2013-2015 ($ millions) Exhibit 47: Galenica: YoY revenue and growth rate of Venofer 2013-2015 ($ millions) Exhibit 48: Pharmacosmos: Key highlights Exhibit 49: Pharmacosmos: Strength assessment Exhibit 50: Pharmacosmos: Strategy assessment Exhibit 51: Pharmacosmos: Opportunity assessment

Allergan, AMAG Pharmaceuticals, Daiichi Sankyo, Galenica, Pharmacosmos, Nippon Shinyaku, NOXXON Pharma, Rockwell Medical, Sanofi, and Wanbang Biopharmaceutical